Clinical Policy: Lysis of Epidural Lesions
Reference Number: CP.MP.116
Last Review Date: 05/20

See Important Reminder at the end of this policy for important regulatory and legal information.

Description
Epidural adhesiolysis, also known as epidural neuroplasty, lysis of epidural adhesions, or caudal neuroplasty, is a minimally invasive surgery for patients with chronic back pain associated with epidural fibrosis or adhesions. Adhesions are commonly caused by scarring after spinal interventions, and are associated with post-laminectomy syndrome or failed back surgery syndrome. Adhesions may also be caused by normal aging of the spine and spinal disorders such as lumbar disc herniation and spinal stenosis.

Policy/Criteria
I. It is the policy of health plans affiliated with Centene Corporation® that lysis of epidural lesions, including percutaneous epidural adhesiolysis and endoscopic epidural adhesiolysis, with or without use of an indwelling epidural Racz catheter, is considered investigational. This treatment continues to be evaluated in clinical studies, however current medical literature does not support its efficacy.

Background
Percutaneous lysis of epidural adhesions with epidural injections of hypertonic saline, in conjunction with steroids and analgesics or hyaluronidase, is an interventional pain management technique that has been investigated as a treatment option in managing chronic intractable low back pain caused by extensive peridural scarring. In theory, the use of hypertonic saline results in a mechanical disruption of the adhesions. Adhesions may also be disrupted by the manipulation of the catheter at the time of the injection. The hypertonic saline may also function to reduce edema within previously scarred and/or inflamed nerves. Hyaluronidase may be added to the injectate to further the penetration of the drugs into the scar tissue.

Spinal endoscopy has been used to guide the lysis of adhesions. Prior to use of endoscopy, adhesions can be identified as non-filling lesions on fluoroscopy. Using endoscopy guidance, a flexible fiberoptic catheter is inserted into the sacral hiatus, providing 3-D visualization to steer the catheter toward the adhesions, to more precisely place the injectate in the epidural space and onto the nerve root. Various protocols for lysis have been described; in some situations the catheter may remain in place for several days for serial treatment sessions.

Evidence for percutaneous adhesiolysis
Controlled trials have found short-term positive effects of percutaneous epidural adhesiolysis in patients with chronic, refractory back pain and lower extremity pain.1-5 However, these studies are limited by methodological limitations including somewhat high attrition rates, insufficient blinding and inadequate statistical power to establish safety. Furthermore, many of the studies were conducted at the same interventional pain management center, which could limit the representativeness of the results obtained by the researchers.1

Evidence for endoscopic adhesiolysis
Clinical Policy  
Lysis of Epidural Lesions  

Research conducted on endoscopic epidural adhesiolysis is generally positive, with significant improvements in pain with endoscopic adhesiolysis compared to control groups.\textsuperscript{6-9} The studies conducted thus far have been largely observational, however.\textsuperscript{6-9} In a 2012 randomized controlled trial (RCT) conducted by Manchikanti et al., endoscopic adhesiolysis was found to significantly improve pain at three, six, and 12 months in patients who had failed conservative treatment for low back pain, compared to endoscopy alone.\textsuperscript{10} A systematic review of endoscopic adhesiolysis was conducted by Helm et al. and included three observational studies and one RCT.\textsuperscript{11} The systematic review concluded that there is fair quality evidence of positive effects, citing paucity of literature as a limitation.\textsuperscript{11}

Guideline Recommendations  
A 2013 Guideline Update by the American Society of Interventional Pain Physicians rates the quality of evidence for lumbar percutaneous adhesiolysis as fair for managing chronic low back and lower extremity pain due to post surgery syndrome and spinal stenosis.\textsuperscript{12} This is due largely to limited number of high quality RCTs assessing the intervention. The guideline update does not address endoscopic adhesiolysis due to limited evidence.\textsuperscript{12} Additionally, the UK National Institute for Clinical Excellence (NICE) has concluded that "current evidence on therapeutic endoscopic division of epidural adhesions is limited to some evidence of short-term efficacy, and there are significant safety concerns. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research."\textsuperscript{13}

Given the limited high quality research conducted on percutaneous and endoscopic adhesiolysis, these procedures are considered investigational.

Coding Implications  
This clinical policy references Current Procedural Terminology (CPT\textsuperscript{®}). CPT\textsuperscript{®} is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2020, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

<table>
<thead>
<tr>
<th>CPT\textsuperscript{®} Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>62263</td>
<td>Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (e.g., catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days</td>
</tr>
<tr>
<td>62264</td>
<td>Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (e.g., catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day</td>
</tr>
</tbody>
</table>

ICD-10-CM Diagnosis Codes
### CLINICAL POLICY

#### Lysis of Epidural Lesions

<table>
<thead>
<tr>
<th>ICD-10-CM Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>G96.12</td>
<td>Meningeal adhesions (cerebral) (spinal)</td>
</tr>
<tr>
<td>G96.198</td>
<td>Other disorders of meninges, not elsewhere classified</td>
</tr>
<tr>
<td>M48.00-M48.08</td>
<td>Spinal Stenosis</td>
</tr>
<tr>
<td>M50.00-M54.9</td>
<td>Other dorsopathies</td>
</tr>
<tr>
<td>M96.1</td>
<td>Postlaminctomy syndrome, not elsewhere classified</td>
</tr>
</tbody>
</table>

**Reviews, Revisions, and Approvals**

<table>
<thead>
<tr>
<th>Description</th>
<th>Date</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy split from CP.MP.63 Pain Management Procedures. Background information added.</td>
<td>07/16</td>
<td>07/16</td>
</tr>
<tr>
<td>References reviewed &amp; updated.</td>
<td>06/17</td>
<td>07/17</td>
</tr>
<tr>
<td>References reviewed and updated. Codes reviewed and updated</td>
<td>04/18</td>
<td>05/18</td>
</tr>
<tr>
<td>References reviewed and updated. Specialist reviewed.</td>
<td>04/19</td>
<td>05/19</td>
</tr>
<tr>
<td>References reviewed and updated. Revised ICD-10 table combining most of the codes listed into a code range.</td>
<td>04/20</td>
<td>05/20</td>
</tr>
<tr>
<td>Revised ICD-10 code G96.19 to G96.198 per 10/1/20 ICD-10 code updates.</td>
<td>10/20</td>
<td></td>
</tr>
</tbody>
</table>

Replaced “member” with “member/enrollee” in all instances.

**References**

CLINICAL POLICY
Lysis of Epidural Lesions


Important Reminder
This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.
This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

Note: For Medicaid members/enrollees, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members/enrollees, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at http://www.cms.gov for additional information.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.